Smart radiation therapy could make stem cell transplants safer for Non-Cancer patients
NCT ID NCT04083183
First seen Jan 02, 2026 · Last updated Jun 21, 2026 · Updated 30 times
Summary
This study tests a new approach to prepare patients with non-cancer blood diseases for a donor stem cell transplant. Instead of high-dose total body radiation, patients receive a radioactive antibody that targets blood-forming cells, aiming to reduce rejection and side effects. The trial involves 40 adults aged 18-50 and is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-MALIGNANT NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Astatine-211-labeled anti-CD45 monoclonal antibody BC8-B10
What this could lead to
If it works, this could offer a safer way to prepare patients with non-cancer blood disorders for a stem cell transplant, reducing the need for total body radiation.
What could go wrong
This is an early phase 1/2 trial with only 40 participants, so results are preliminary. The radioactive antibody may cause side effects like organ damage or graft-versus-host disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.